

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/679,081	10/03/2003	Hans-Michael Dosch	2560.001	3553
21917 7	590 03/24/2005		EXAM	INER
MCHALE & SLAVIN, P.A.			LIETO, LOUIS D	
2855 PGA BLVD PALM BEACH GARDENS, FL 33410			ART UNIT	PAPER NUMBER
	,		1632	

DATE MAILED: 03/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

-	Application No.	Applicant(s)				
	10/679,081	DOSCH ET AL.				
Office Action Summary	Examiner	Art Unit				
	Louis D. Lieto	1632				
The MAILING DATE of this communica Period for Reply	tion appears on the cover sheet wi	th the correspondence address				
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA  - Extensions of time may be available under the provisions of 3 after SIX (6) MONTHS from the mailing date of this communic  - If the period for reply specified above is less than thirty (30) do  - If NO period for reply is specified above, the maximum statutor  - Failure to reply within the set or extended period for reply will,  Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	ATION. 7 CFR 1.136(a). In no event, however, may a restion. ays, a reply within the statutory minimum of thirthy period will apply and will expire SIX (6) MON by statute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed of	on					
2a) This action is <b>FINAL</b> . 2b)	nis action is FINAL. 2b) This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ⊠ Claim(s) <u>1-5</u> is/are pending in the applied 4a) Of the above claim(s) is/are versions.  5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are rejected.  7) □ Claim(s) is/are objected to.  8) ⊠ Claim(s) <u>1-5</u> are subject to restriction and	withdrawn from consideration.					
Application Papers						
9)☐ The specification is objected to by the E	xaminer.					
	)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection		• •				
Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by		• •				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for a) All b) Some * c) None of:  1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of t application from the International * See the attached detailed Office action for	cuments have been received. cuments have been received in Ap he priority documents have been Bureau (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Se	ummary (PTO-413)				
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-3)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date</li> </ol>		)/Mail Date formal Patent Application (PTO-152) 				

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1 and 4, drawn to a process for monitoring or diagnosing primary
   Sjogren's Syndrome, classified in class 435, subclass 7.1.
- II. Claims 2 and 5, drawn to an immunotherapeutic process of treating primarySjogren's Syndrome, classified in class 514, subclass 2.
- III. Claim 3, drawn to a transgenic NOD congenic mouse characterized by inactivation of the genomic ICA69 locus, classified in class 435, subclass 325.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, and III, are patentably distinct. In the instant case the different inventions of group I is drawn to a process for monitoring or diagnosing primary Sjogren's Syndrome, while the invention of group II is drawn to an immunotherapeutic process of treating primary Sjogren's Syndrome, and the invention of group III is drawn to a transgenic NOD congenic mouse characterized by inactivation of the genomic ICA69 locus. The inventions of groups I and II do not require a transgenic NOD congenic mouse model, nor can they be used to make a transgenic mouse, which is structurally and functionally different then the inventions of groups I and II. Further, the invention of group I is functionally different than the invention of group II, since group I requires the drawing of blood to diagnose or monitor primary Sjogren's Syndrome, while the invention of group II reads on a method of treatment of primary Sjogren's Syndrome with a peptide. The primary Sjogren's Syndrome of group II could be identified in a

Page 3

materially different fashion than the process of group I, such as by the Schirmer test. Finally the primary Sjogren's Syndrome of group I could be treated with nonsteroidal anti-inflammatory drugs. None of the inventions require the others in order to be practiced.

Furthermore, searching the inventions of groups I-III together would impose a serious search burden. In the instant case, the search of a transgenic mouse characterized by inactivation of the genomic ICA69 locus, a method of diagnosing or monitoring primary Sjogren's Syndrome, and a method of treating primary Sjogren's Syndrome are quite different. The methods are structurally and functionally different from a transgenic mouse and from each other. The transgenic mouse could be made and used in multiple different and independent ways; thus, the making and use of the mouse encompass separate searches of the art. Finally, a method of diagnosing and treating diseases are functionally distinct from each other. Thus, the search of groups I-III is not co-extensive. Finally, the inventions of groups I-III have a separate status in the art as shown by their different sub-classifications. As such, it would be burdensome to search the inventions of groups I-III together.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Lou Lieto whose telephone number is (571) 272-2932. The examiner can normally be reached on Monday-Friday, 9am-5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571)-272-0735. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available Art Unit: 1632

through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Patent applicants with problems or questions regarding electronic images that can be viewed in the PAIR can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-

9199.

Dr. Louis D. Lieto Patent Examiner Art Unit 1632

RAM R. SHUKLA, PH.D.

RAM R. SHUKLA, PH.D.

RAMINER

ROUSORY PATENT EXAMINER